21st week of 2013 patent applcation highlights part 59 |
Patent application number | Title | Published |
20130131089 | DOSAGE FORMS OF ELINOGREL AND METHODS OF INJECTABLE ADMINISTRATION THEREOF - The present invention is concerned with a liquid delivery form of Elinogrel for the treatment of thrombosis which is notable for its improved dosage properties and stability. The dosage form is a liquid or a lyophilized form which is reconstituted for an injectable formulation comprising: a) at least about 3 mg/ml or up to about 15 mg/ml Elinogrel or a pharmaceutically acceptable salt thereof (post reconstitution or in liquid form), and b) at least one pharmaceutically acceptable excipient. Further aspects of the present invention concern the preparation and use of such a formulation. | 2013-05-23 |
20130131090 | SALTS OF LAPATINIB - The present invention provides novel dioxalate salt of lapatinib, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides novel monobesylate salt of lapatinib, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides a process for the preparation of monohydrate form of lapatinib ditosylate. The present invention further provides a process for the preparation of anhydrous form of lapatinib ditosylate. | 2013-05-23 |
20130131091 | HARMFUL ORGANISM CONTROL AGENT - The present invention provides a composition for use as a harmful organism control agent comprising as an active ingredient one or more of compounds represented by formula (I) or salts thereof and an agriculturally or zootechnically acceptable carrier. | 2013-05-23 |
20130131092 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds of Formula (I), wherein X | 2013-05-23 |
20130131093 | Novel Dihydropyrimidin-2(1H)-One Compounds As Neurokinin-3 Receptor Antagonists - The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as Neurokinin-3 (NK3) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2013-05-23 |
20130131094 | PYRIMIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS - Pyrimidine deriviatives are ubiquination inhibitors that inhibit the ubiquitin ligase activity, particularly of POSH polypeptides, are useful for the treatment of viral infections and neurological disorders. | 2013-05-23 |
20130131095 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS - The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, | 2013-05-23 |
20130131096 | 8-HYDROXY-QUINOLINE DERIVATIVES - The invention relates to compounds of the general formula (I) and their pharmaceutically acceptable salts (in which formula R | 2013-05-23 |
20130131097 | TOPICAL TREATMENT FOR CHEMOTHERAPY INDUCED EYELASH LOSS OR HYPOTRICHOSIS USING PROSTAMIDE F2 ALPHA AGONISTS - The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment. | 2013-05-23 |
20130131098 | PHARMACEUTICAL FORMULATION OF APOMORPHINE FOR BUCCAL ADMINISTRATION - The present invention provides a kit comprising, in separate compartments of a container, the following components (a) and (b): (a) a combination of apomorphine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient or carrier; and (b) a solution which comprises a diluent and a pH modifying agent; the components being presented such that they can be combined at the point of use into a formulation which is adjusted to a pH ranging from mildly acidic to alkaline and which is suitable for buccal administration. The formulation is useful in treating Parkinson's disease and in promoting sexual function. | 2013-05-23 |
20130131099 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS - Nitrated and non-nitrated compounds capable of protecting brain tissue from injury and useful as therapeutic agents to treat neurodegenerative diseases and conditions are disclosed. Methods of using the compounds in therapeutic treatments, and methods of preparing the compounds, also are disclosed. | 2013-05-23 |
20130131100 | HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS AND USES THEREOF - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 2013-05-23 |
20130131101 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD - A medication comprising tetrahydropyridoethers for use in the treatment of AMD. | 2013-05-23 |
20130131102 | SELECTIVE GLYCOSIDASE INHIBITORS - The present invention provides glucoimidazole derivatives and methods of making them. The compounds can be used to inhibit the activity of O-GlcNAcase enzymes, including both bacterial OGA (bOGA) and human OGA (hOGA) and can be selective, showing low inhibition of hexosaminidases. The compounds can be used to study the role of the O-GlcNAcase modification in human or animal cells. Furthermore the compounds can have therapeutic uses in the treatment of diseases mediated by the activity of O-GlcNAcase enzymes including type II diabetes, Alzheimers Disease, and cancer. | 2013-05-23 |
20130131103 | Methods and Compositions For Improved Nerve Conduction Velocity - The present invention provides methods and compositions for the effective treatment of impaired nerve signal conduction. Compositions including selective AT | 2013-05-23 |
20130131104 | HISTIDINE RICH PROTEIN-2 DIAGNOSTIC TEST FOR CEREBRAL MALARIA - The present inventions relate to accurately identifying a subset of patients within a larger group with malarial parasitemia. In particular, the present inventions provide compositions and methods comprising a malarial protein, histidine rich pro-tein-2 (HRP-2) for determining the general severity of a malarial infection in patients. Specifically, the inventions provide a rapid test comprising a read-out for HRP-2 levels in bodily fluids for determining whether a comatose patient's disease is a result of malaria as opposed to coma of another cause with incidental parasitemia. Specifically, in one preferred embodiment, a rapid test is contemplated as a quantitative rapid test dipstick. Further, these inventions relate to predictive tests for patients at risk for progression of relatively mild malaria disease to the more life-threatening cerebral malaria in addition to determining the etiology of malaria infections in comatose patients. | 2013-05-23 |
20130131105 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2013-05-23 |
20130131106 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE - This invention relates to synthetic bifunctional compounds comprising a first rho-associated kinase (ROCK) inhibiting compound and a second pharmaceutically active compound with complementary activity; the first and the second compounds are covalently linked by a biologically labile bond. This invention also relates to methods of making such compounds. The invention also relates to methods of using such bifunctional compounds in the prevention or treatment of diseases or conditions that are affected or can be assisted by altering the integrity or rearrangement of the cytoskeleton. Particularly, this invention relates to methods of treating ophthalmic diseases such as disorders in which intraocular pressure is elevated, for example primary open-angle glaucoma, using the bifunctional compounds. | 2013-05-23 |
20130131107 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis. | 2013-05-23 |
20130131108 | METHODS OF TREATING OBSTRUCTIVE LUNG DISEASES USING BITTER TASTANTS - Described herein are methods for enhancing airway dilation and/or relieving bronchoconstriction, e.g., to treat obstructive lung diseases such as asthma and COPD, by administering bitter tastants to subjects in need thereof. Also described herein are methods for identifying compounds that modulate function of bitter tastant receptors. | 2013-05-23 |
20130131109 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS - Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions. | 2013-05-23 |
20130131110 | Compositions for the Treatment of CNS-Related Conditions - The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. | 2013-05-23 |
20130131111 | NMN MODULATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS - The invention relates to a nicotinamide mononucleotide (NMN) modulator useful as a neuroprotective medicament in the treatment of neurodegenerative disorders, in particular but not exclusively disorders involving axon degeneration of neuronal tissue such as Wallerian degeneration, to the use of NMN as a biomarker for axon degeneration, to a method of demonstrating axon degeneration using an NMN-based biomarker, to a diagnostic kit for detecting axon degeneration, to a method of screening for an NMN modulator, and to an NMN modulator identified using the aforementioned screening method. | 2013-05-23 |
20130131112 | SALTS OF 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)PIPERIDINE-2,6-DIONE AND DERIVATIVES THEREOF, OR POLYMORPHS OF SALTS, PROCESS FOR PREPARING SAME AND USE THEREOF - The present invention provides a pharmaceutically acceptable strong acid salt of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione, a solvate thereof, a process for preparing the same and use in the preparation of a medicament for treating diseases or physiological abnormities by inhibiting inflammatory factors or angiogenesis. The water-solubility of the pharmaceutically acceptable strong acid salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione is quite higher than that of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione. The present invention also provides polymorphs of a pharmaceutically acceptable strong acid salt of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and a solvate thereof. | 2013-05-23 |
20130131113 | PYRIDONE GLUCOKINASE ACTIVATORS - Provided herein are compounds of the formula (I): | 2013-05-23 |
20130131114 | NOVEL ALKENE OXINDOLE DERIVATIVES - The present invention provides compounds of formula (I), | 2013-05-23 |
20130131115 | PEST CONTROL COMPOSITION - A pest control composition comprising a hydrazide compound shown by formula (1) below (in the formula, G, M, Q | 2013-05-23 |
20130131116 | PEST CONTROL COMPOSITION - A pest control composition comprising a hydrazide compound shown by formula (1) below (in the formula, G, M, Q | 2013-05-23 |
20130131117 | PEST CONTROL COMPOSITION - A pest control composition comprising a hydrazide compound shown by formula (1) below (in the formula, G, M, Q | 2013-05-23 |
20130131118 | PEST CONTROL COMPOSITION - A pest control composition comprising a hydrazide compound shown by formula (1) below (in the formula, G, M, Q | 2013-05-23 |
20130131119 | N-[(HET)ARYLETHYL)] PYRAZOLE(THIO)CARBOXAMIDES AND THEIR HETEROSUBSTITUTED ANALOGUES - The present invention relates to fungicidal N-[(het)arylethyl)] pyrazolecarboxamide or thiocarboxamide and their heterosubstituted analogues, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. | 2013-05-23 |
20130131120 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR NEUROPATHIC PAIN - A therapeutic agent or a prophylactic agent for neuropathic pain provides a synergistically-enhanced analgesic effect at a dose at which a calcium channel α2δ ligand does not produce any side effects as well as which agent does not produce any new side effects on the central nervous system. The therapeutic agent or a prophylactic agent for neuropathic pain includes as effective ingredients a cyclohexane derivative, represented by the following formula, or a pharmaceutically acceptable salt thereof or a prodrug thereof, and a calcium channel α2δ ligand. | 2013-05-23 |
20130131121 | ANTI-VIRAL AGENT - A method of suppressing the proliferation of virus comprises administering an antiviral agent comprising as an effective component at least one member selected from the group consisting of 5,7,4′-trihydroxy-3′,5′-dimethoxyflavone, 3-hydroxypyridine, p-hydroxybenzaldehyde and vanillin to one in need of suppressing of viral proliferation. | 2013-05-23 |
20130131122 | Fluro substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions - A compound of Formula (I): | 2013-05-23 |
20130131123 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - An immediate release solid dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor, comprising a PDE 4 inhibitor that is N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast) or a salt thereof, and one or more suitable pharmaceutical excipients; wherein said dosage form contains 500 μg of the roflumilast or salt thereof. | 2013-05-23 |
20130131124 | O-CYCLOPROPYLCYCLOHEXYL-CARBOXANILIDES AND THEIR USE AS FUNGICIDES - The present invention relates to O-CYCLOPROPYLCYCLOHEXYL-CARBOXANILIDES derivatives of formula (I); their process of preparation, their use as fungicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. | 2013-05-23 |
20130131125 | THERAPEUTIC COMBINATION - This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans. | 2013-05-23 |
20130131126 | DERIVATIVES OF 1,4-DIHYDROPYRIDINE POSSESSING ANTIVIRAL EFFICACY - 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid ester type compounds having general formula I | 2013-05-23 |
20130131127 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS - Method of using dopamine reuptake inhibitors, e.g., sydnonimine derivatives, for the management of diabetic symptoms and associated complications or conditions, such as hyperglycemia and diabetic neuropathy. | 2013-05-23 |
20130131128 | ASSOCIATION OF XANTHINE OXIDASE INHIBITORS AND ANGIOTENSIN II RECEPTOR ANTAGONISTS AND USE THEREOF - The present invention relates to an association of active principles, i.e. of a xanthine oxidase inhibitor with one or more angiotensin II receptor antagonists, pharmaceutical compositions comprising said active principles, for use in a therapeutic treatment in humans or animals, and methods for the preparation thereof. | 2013-05-23 |
20130131129 | Reversing Intestinal Inflammation by Inhibiting Retinoic Acid Metabolism - An agent that increases local concentration of retinoic acid (RA) in the intestine through modifying enzymatic pathways involved in RA metabolism is administered in a dose effective to inhibit or reverse production of inflammatory mediators by intestinal dendritic cells and thereby reduce intestinal inflammation and tumor growth associated with intestinal inflammation. | 2013-05-23 |
20130131130 | SYNERGISTIC PRESERVATIVE COMPOSITIONS - A preservative composition comprising: (a) 1,2-Benzisothiazolin-3-one (BIT); (b) 3-Iodo-2-propynyl carbamate (IPBC); and (c) a mixture of 5-Chloro-2-methyl-4-isothiazolin-3-one (CMIT) and 2-Methyl-4-isothiazolm-3-one (MIT). | 2013-05-23 |
20130131131 | Bendamustine Pharmaceutical Compositions - The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases. | 2013-05-23 |
20130131132 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY - The present invention relates to N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives of the formula (I), (II), (III) or (IV) | 2013-05-23 |
20130131133 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES - The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement. | 2013-05-23 |
20130131134 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF - A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA | 2013-05-23 |
20130131135 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid. The compound may be represented by the following formula | 2013-05-23 |
20130131136 | NOVEL METHODS FOR PREDICTING THE RESPONSIVENESS OF A PATIENT AFFECTED WITH A TUMOR TO A TREATMENT WITH A TYROSINE KINASE INHIBITOR - The present invention relates to a method for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor such as sunitinib. More specifically, the method of the invention comprises a step of determining the expression level of one marker consisting of the FSHR in a biological sample obtained from said patient, and more specifically in the blood endothelial cells from the tumors. | 2013-05-23 |
20130131137 | INSECTICIDAL COMPOUNDS - The invention relates to compounds of formula (I) where A | 2013-05-23 |
20130131138 | NOVEL FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b,d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4- -[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID MAGNESIUM - Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described. | 2013-05-23 |
20130131139 | ROR1 AS A GENE TARGET IN ACUTE LYMPHOBLASTIC LEUKEMIA - Disclosed are methods of selecting a subject suspected of having or having leukemia, such as lymphoblast leukemia (B-ALL), for treatment with an agent that inhibits ROR1-regulated signaling activity. In some examples, cells obtained from the subject are screened for over expression of ROR1. In other examples, the cells are contacted with an agent that inhibits ROR1 signaling activity and a ROR1-regulated signaling activity is detected. An alteration in the ROR1-regulated signaling activity as compared to a control identifies the subject as one that would benefit from treatment with an agent that inhibits ROR1 signaling activity. Also disclosed are methods for identifying an agent for treating a subject with a ROR1-dependent leukemia or with a predisposition for developing a ROR1-dependent leukemia, and methods for treating or inhibiting a ROR1-dependent leukemia, such as B-ALL in a subject. | 2013-05-23 |
20130131140 | TREATMENT OF DIABETES AND DISORDERS ASSOCIATED WITH VISCERAL OBESITY WITH INHIBITORS OF HUMAN ARACHIDONATE 12 LIPOXYGENASE AND ARACHIDONATE 15-LIPOXYGENASE - A basis for understanding the arachidonate 12-lipoxygenase pathway, as well as and methods and kits for inhibiting the arachidonate 12-lipoxygenase pathway for the treatment, reversal, reduction, modulation or prevention of disease states and conditions related to type 1 or type 2 diabetes, are disclosed. Also disclosed are inflammatory forms of ALOX12 and 15, which are selectively expressed in omental adipose tissue of obese humans. Inhibitors of ALOX12 and 15 can be used to treat, prevent, modulate or reduce complications associated with increased visceral obesity and inflammation, including type 2 diabetes. Also disclosed are methods for developing selective ALOX inhibitors for treating or reducing complications associated with increased visceral obesity and inflammation. | 2013-05-23 |
20130131141 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS - The present invention relates to methods for in vivo administration of sd-rxRNA molecules. | 2013-05-23 |
20130131142 | RNA INTERFERENCE IN OCULAR INDICATIONS - The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules. | 2013-05-23 |
20130131143 | RTP801L SIRNA COMPOUNDS AND METHODS OF USE THEREOF - The invention provides chemically modified siRNA oligonucleotides that target RTP801L, compositions comprising same and to the use of such molecules to treat, inter alia, respiratory diseases including acute and chronic pulmonary disorders, eye diseases including glaucoma and ION, microvascular disorders, angiogenesis- and apoptosis-related conditions, and hearing impairments. | 2013-05-23 |
20130131144 | GDE Compositions and Methods - The present invention relates to compositions to treat glycerophosphodiester phosphodiesterase (GDE) related disorders. The invention also relates to methods treating GDE related disorders. The invention further relates to kits for treating GDE related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating GDE related disorders in a subject. | 2013-05-23 |
20130131145 | COMPOSITIONS AND METHODS FOR ALTERING RNAi - The present invention relates to compositions and methods for altering (e.g., enhancing) RNAi. In particular, the present invention provides systems and methods for identifying regulators of RNAi. For example, the present invention provides RNAi regulators (e.g., HPS1 and HPS4) and methods of altering (e.g., inhibiting) these regulators in order to alter (e.g., enhance) RNAi. The present invention also provides methods of identifying inhibitors (e.g., small molecule, nucleic acid (e.g., siRNA), and antibody) of RNAi regulators and methods of using the same (e.g., to enhance RNAi). Compositions and methods of the present invention find use in research (e.g., functional genomics), therapeutic (e.g., drug discovery and delivery) and clinical applications. | 2013-05-23 |
20130131146 | Compositions and Methods for Treating Pulmonary Conditions - The present invention relates to the role of cystic fibrosis transmembrane conductance regulator (CFTR) in pulmonary conditions. In one embodiment, a method for assessing the severity of lung damage from a pulmonary condition in a subject comprises the steps of (a) measuring the level and/or functional activity of membrane/lipid-raft cystic fibrosis transmembrane conductance regulator (CFTR)in a sample from the subject; (b) measuring the level of ceramide or its species in a sample from the subject; and (c) comparing the membrane/lipid- raft CFTR level and/or functional activity and ceramide level to a control sample, wherein a difference in membrane/lipid-raft CFTR level and/or functional activity and ceramide level is indicative of the severity of lung damage. The method can further comprise treating the subject based on the severity of lung damage. In particular embodiments, the treatment comprises administering a CFTR agonist and/or an agent that inhibits the synthesis of ccramide or its species. | 2013-05-23 |
20130131147 | SUBSTITUTED 2'-AMINO AND 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM - Provided herein are 2′-amino and 2′-thio bicyclic nucleosides and oligomenc compounds prepared therefrom. The novel bicyclic nucleosides provided herein are expected to be useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance. | 2013-05-23 |
20130131148 | MICRO-RNA FOR CANCER DIAGNOSIS, PROGNOSIS AND THERAPY - The present invention relates to polymorphic binding sites for micro-RNA and to micro-RNA-based cancer diagnosis, cancer therapy and personalized medicine. In particular, the present invention relates to diagnosis, therapy and personalized medicine with the specific miR-515-5p molecule. | 2013-05-23 |
20130131149 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANDROGEN RECEPTOR BY DOUBLE-STRANDED RNA - This invention relates to compounds, compositions, and methods useful for reducing AR target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents. | 2013-05-23 |
20130131150 | Antisense Formulation - A room temperature stable and minimal aggregate liquid formulation comprises an oligonucleotide comprising Seq ID No. 1: or comprising a variant oligonucleotide in which no more than 3 non-sequential bases are different from Seq. ID NO. 1 and an aqueous carrier comprising a aggregation-preventing compound selected from the group consisting of mono and disaccharides and/or sugar alcohols. | 2013-05-23 |
20130131151 | METHOD FOR PHOTOPOLYMERIZING HYDROGEL USING X-RAY IRRADIATION - A method for preparing a hydrogel includes the steps of injecting a precursor with at least two alkene groups into a predetermined portion, injecting at least one specie into the predetermined portion, and performing an X-ray irradiation on the predetermined portion to induce a polymerization reaction of the precursor to form a porous hydrogel with the specie embedded inside the porous hydrogel. In one embodiment of the present invention, the specie is selected from the group consisting of nucleic acid and adhesion agent. | 2013-05-23 |
20130131152 | HYPOXIA REGULATED CONDITIONALLY SILENCED AAV EXPRESSING ANGIOGENIC INDUCERS - Methods and compositions for the treatment of hypoxia associated disorders by directional angiogenesis/arteriogenesis. Conditionally silenced vectors expressing a therapeutic molecule under hypoxic conditions avoid chaotic vascularization and allow for the orderly growth of new vessels into damaged tissue. | 2013-05-23 |
20130131153 | CULLIN 5 AS A REGULATOR OF HSP90 CLIENTS: A NEW TARGET FOR DRUG DEVELOPMENT - Cullin5 (Cul5) E3 ubiquitin ligase is shown to be linked with the heat shock protein 90 (Hsp90) chaperone complex. Hsp90 participates in the folding of its client proteins into their functional conformation. Many Hsp90 clients have been reported to be aberrantly expressed in a number of cancers. Cul5 is shown to interact with members of the Hsp90 chaperone complex as well as the Hsp90 client, ErbB2, Cul5 is recruited to the site of ErbB2 at the plasma membrane and subsequent induction of polyubiquitination and proteasomal degradation. Cul5 is also involved in the regulation of another Hsp90 client, Hif-1α Cul5 degradation of ErbB2 occurs independently of ElonginB-ElonginC function. The involvement of Cul5 in Hsp90 client regulation has implications in the effectiveness of Hsp90 targeted chemotherapy, which is currently undergoing clinical trials. The link between Cul5 and Hsp90 client regulation may represent an avenue for cancer drug development. | 2013-05-23 |
20130131154 | Nonviral Gene Delivery Vector Iopamidol, Protamine, Ethiodized Oil Reagent (Viper) - Embodiments are related to nonviral gene delivery vectors using only FDA-approved components: iopamidol, protamine, and ethiodized oil. | 2013-05-23 |
20130131155 | Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates - The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer. | 2013-05-23 |
20130131156 | Cancer Treatment with Wortmannin Analogs - Provided herein are certain therapeutically effective dosing regimens for treatment of cancers with wortmannin analogs. | 2013-05-23 |
20130131157 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS - Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C | 2013-05-23 |
20130131158 | ANTIVIRAL COMPOSITION - The present invention relates to a composition of phenolic antioxidants obtained from oil palm, and more particularly this invention relates to a composition for promoting immunity in general and most essentially against Human Immunodeficiency Virus (HIV) related infections. Accordingly, the composition having the said oil palm compounds can effectively inhibit various viruses, further supporting oil palm compounds as one of the broad spectrum antiviral drugs. | 2013-05-23 |
20130131159 | PLECTRANTHUS AMBOINICUS FRACTION HAVING ANTI-ARTHRITIS ACTIVITY - The invention provides an extract of | 2013-05-23 |
20130131160 | NEW USE OF HESPERETIN - The present invention discloses a use of hesperetin or a hesperetin-containing plant extract in the manufacture of a product for improving and/or promoting skin microcirculation, or for eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation. The present invention also discloses a composition comprising an effective amount of hesperetin or a hesperetin-containing plant extract, and to a method for improving and/or promoting skin microcirculation, or eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation, by using hesperetin. The skin microcirculation of the present invention is preferably eye skin microcirculation. | 2013-05-23 |
20130131161 | METHODS AND COMPOSITIONS FOR CARDIOVASCULAR DISEASES AND CONDITIONS - Embodiments of the invention are directed to identifying or treating a patient that would benefit from phosphodiesterase inhibitor therapy. | 2013-05-23 |
20130131162 | Vitamin C Composition for Use in the Prevention and Treatment of Stretch Marks, Radiation Dermatitis, and Other Skin Conditions and Methods of Using the Same - A formulation for a stable ascorbic acid composition which, in a simplified form, is comprised of ascorbic acid in solution with a hygroscopic compound (i.e., a substance with the ability to attract water molecules from the surrounding environment through either absorption or adsorption). Also disclosed herein are methods for the production of such compounds and methods of using such compounds in the prevention, inhibition and treatment of striae gravidarum, radiation dermatitis, rhytids, lentigoes, dyschromia, sun-damage induced hyperpigmentation, cellulite, scars and purpura, among other skin diseases or conditions. | 2013-05-23 |
20130131163 | Vitamin C Composition for Use in the Prevention and Treatment of Stretch Marks, Radiation Dermatitis, and Other Skin Conditions and Methods of Using the Same - A formulation for a stable ascorbic acid composition which, in a simplified form, is comprised of ascorbic acid in solution with a hygroscopic compound (i.e., a substance with the ability to attract water molecules from the surrounding environment through either absorption or adsorption). Also disclosed herein are methods for the production of such compounds and methods of using such compounds in the prevention, inhibition and treatment of striae gravidarum, radiation dermatitis, rhytids, lentigoes, dyschromia, sun-damage induced hyperpigmentation, cellulite, scars and purpura, among other skin diseases or conditions. | 2013-05-23 |
20130131164 | STABILIZED PHENYLCARBAMATE DERIVATIVE IN SOLID STATE - The invention relates to retigabine with improved color quality, and to processes for preparing the same. In addition, the invention relates to a process for drying wet retigabine. Also, the invention relates to stabilized or substantially stabilized retigabine in solid state, or a mixture or pharmaceutical formulation comprising the same. Further, the invention also relates to an improved process for preparing retigabine. | 2013-05-23 |
20130131165 | PROCESS FOR PRODUCTION OF PURIFIED CHLOROGENIC ACID-CONTAINING PHARMACEUTICAL PREPARATION - Provided is a process for producing a purified chlorogenic acid-containing preparation, which is useful for the production of a chlorogenic acid-containing beverage with reduced developability of turbidity even in an acidic range. | 2013-05-23 |
20130131166 | BIOADHESIVE COMPOSITIONS FOR EPITHELIAL DRUG DELIVERY - Disclosed are compositions and methods for treating a disease, such as infection, pain, or inflammation, by using the compositions. Particularly, disclosed is a method of treating oral pain, wherein, the above-described compositions are applied to the oral mucosa; the compositions undergo in-situ gelation, optimal adhesion to the oral mucosa, controlled erosion and controlled release of the active ingredient, i.e., benzocaine, which provides a superior degree of pain relief or analgesia for an extended period of time. | 2013-05-23 |
20130131167 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS - This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss. | 2013-05-23 |
20130131168 | 1-MONOPROPIONINE COMPOUND AND ITS ISOMER 3-MONOPROPIONINE AS PRESERVING AGENTS FOR ANIMAL FEED, GRAINS AND ANIMAL-ORIGIN MEALS - An application method of 1-monopropionine compound and its isoform 3-monopropionine being used as preserving agents in animal feeds, corns, grains, and other food materials. The monopropionine compounds are obtained by esterification reaction of propionic acid and glycerol. The product is a translucent viscous liquid composition comprising monopropionine compounds and other components, such as free acid, or certain salt forms of propionate. The generated composition can be further distilled in glycerol. The final product can take a liquid form or a powder form. 1-monopropionine compound and its isoform 3-monopropionine function as preserving agent at a low effective dosage of about 0.05 to 1% (by weight), and preferably 0.1 to 0.3% (by weight). A preferable application condition of this method is to preserve animal feeds and corns under a low (about 2% to 12%) moisture condition. | 2013-05-23 |
20130131169 | COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME - Disclosed is a cooling sensation agent composition or sensory stimulation agent composition which contains at least one of diester compounds of dicarboxylic acid represented by the formula (1) wherein A represents CH | 2013-05-23 |
20130131170 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2013-05-23 |
20130131171 | Treatment for Meibomian Gland Dysfunction or Obstruction - A jojoba formulation has been developed for administration to the meibomian gland, for treatment of the symptoms of dry eye, and/or for drug delivery to the meibomian gland. The formulation incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear as well as stabilize the tear film. The jojoba wax tear relieves irritation and discomfort as well as sharpens the blurred vision. Jojoba, because of its close chemical and physical properties to meibomian gland secretions, is effective upon topical application to penetrate the lid margin to reach the gland tissues where it may exert a therapeutic effect with or without an adjunctive agent. | 2013-05-23 |
20130131172 | NOVEL ANTIMICROBIAL COMPOUNDS AND USES THEREOF - The present invention relates to novel antimicrobial compounds, methods of their production as well as uses thereof. | 2013-05-23 |
20130131173 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID SUITABLE FOR HIGH PURIFICATION - The invention relates to a microbial biomass composition produced from a heterotrophic fermentation whose fatty acid profile exhibits: an eicosapentaenoic acid (EPA) to arachidonic acid (ARA) ratio of about 11:1 or more; an EPA to total co-concentrating fatty acid ratio of about 8:1 or more, extract compositions, and methods of producing such compositions. | 2013-05-23 |
20130131174 | INJECTABLE PHARMACEUTICAL FORMULATION OF MELPHALAN - An injectable pharmaceutical formulation of Melphalan comprising a solid composition of melphalan hydrochloride lyophilized with a content of impurities up to 1.3% (p/p)and a pH buffer solution; a process to prepare said solid composition. Also a reconstituted solution of melphalan comprising a solid composition of melphalan lyophilized reconstituted wherein said solution is aqueous, a perfusion free of organic solvent and a kit. | 2013-05-23 |
20130131175 | CREATINE ORAL SUPPLEMENTATION USING CREATINE HYDROCHLORIDE SALT - The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine. | 2013-05-23 |
20130131176 | High Concentration Baclofen Preparations - Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions. | 2013-05-23 |
20130131177 | USE OF A DERMATOLOGICAL COMPOSITION COMPRISING A COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE WHICH IS INTENDED FOR THE TREATMENT OF ACNE IN NON-CAUCASIAN POPULATION WITH DECREASE OF POST-INFLAMMATORY HYPERPIGMENTATION - A dermatological composition including a combination of Adapalene and benzoyl peroxide is described. The composition is intended for the treatment of acne in the non-Caucasian population with decreased post-inflammatory hyperpigmentation, keloid scarring and acne hyperpigmented macules and cystic lesions. | 2013-05-23 |
20130131178 | USE OF OXALOACETATE IN THE TREATMENT OF ISCHAEMIA - The invention relates to the use of oxaloacetate in the treatment of ischaemia. The invention provides quantities that are therapeutically effective for the treatment of disorders associated with high levels of glutamate in brain tissue, such as, for example, cerebral ischaemia. In addition, the compositions of the invention are suitable for bolus-type delivery. | 2013-05-23 |
20130131179 | IRON METABOLISM-IMPROVING AGENT - An acetic acid- and/or acetate salt-free iron metabolism-improving agent that contains citric acid and/or a citrate salt as electrolytes and also contains another/other electrolyte/electrolytes and glucose solely or in combination is provided. The iron metabolism-improving agent can be formulated into a dialysate and/or a substitution fluid. A method for improving internal iron metabolism and a blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing the dialysate and/or the substitution fluid are further provided. | 2013-05-23 |
20130131180 | N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICAMENT CONTAINING SAME - A compound represented by the following general formula (I) which has ADAM17 inhibitory activity, or a salt thereof, or a solvate thereof: | 2013-05-23 |
20130131181 | USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS - The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas. | 2013-05-23 |
20130131182 | PTP1B INHIBITORS, SYNTHESIS THEREOF AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR TREATING TYPE 2 DIABETES MELLITUS - The present invention relates to chemical total synthesis methods of six novel protein tyrosine phosphatase-1B (PTP1B) inhibitors and application of the inhibitors in the preparation of medicaments for treating type 2 diabetes mellitus (T2DM). The PTP1B inhibitors use one or more of the six compounds represented by the structural formulae 1, 2, 3, 4, 5 and 6, as active components. The compounds can enhance the sensitivity of an insulin receptor by inhibiting the activity of PTP1B, thereby having a favorable therapeutic effect on insulin-resistant T2DM. | 2013-05-23 |
20130131183 | METHODS AND COMPOSITIONS FOR IMPROVING THE HEALTH OF ANIMALS - The invention features compositions and methods for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for improving the health of animals, such as increasing joint mobility, increasing activity, and improving coat quality. | 2013-05-23 |
20130131184 | ASTAXANTHIN-CONTAINING AQUEOUS COMPOSITION, COSMETIC PREPARATION, AND METHOD FOR SUPPRESSING DECOMPOSITION OF ASTAXANTHIN - Disclosed are an aqueous cosmetic preparation including at least astaxanthin, 20 μg/L or more of iron ions, and an iron chelating agent, and a method for suppressing the decomposition of astaxanthin in which an iron chelating agent is included in an aqueous composition including at least astaxanthin and 20 μg/L or more of iron ions. | 2013-05-23 |
20130131185 | Methods and Compositions for Control of Cabbage Looper, Trichoplusia ni - The invention provides in part dialkoxybenzene compounds for controlling infestation by a | 2013-05-23 |
20130131186 | Microemulsion Preparation of High Concentration Propofol for Anesthetic Uses - The invention provides a method and a composition for enhancing the dissolution and bioavailable properties of propofol (2, 6 diisopropyl phenol) for use as an intravenously administered anesthetic in mammals. The method produces a self-microemulsifyable emulsion base composition that is utilized in the production of a water-based microemulsion preparation. In a preferred two (2) component base composition, the base composition consists of: a surfactant, containing polyethylene glycol; and liquid propofol. The microemulsion is prepared by mixing the base composition with a carrier liquid, which results in the formation of a microemulsion containing concentrations of propofol of up to about 4% by weight of propofol to the volume of the microemulsion. In a four (4) component base composition, the base composition consists of: a surfactant, containing polyethylene glycol; liquid propofol; a water-immiscible solvent; and ethanol. The microemulsion is prepared by mixing the base composition with a carrier liquid, which results in the formation of a microemulsion containing concentrations of propofol of up to about 10% by weight of propofol to the volume of the microemulsion. | 2013-05-23 |
20130131187 | COLOR METALLIC PIGMENT, METHOD FOR PRODUCING SAME, AND COATING COMPOSITION AND COSMETIC CONTAINING SAME - A color metallic pigment according to the present invention contains at least a metallic pigment, an amorphous silicon oxide film layer that is formed on the surface of the metallic pigment, a metal oxide layer that is formed on the surface of the amorphous silicon oxide film layer and contains a metal oxide other than silicon oxide, and metal particles that are formed on the surface of the metal oxide layer, wherein the metal particles are so formed as to directly cover a part of the metal oxide layer. | 2013-05-23 |
20130131188 | Cosmetic Preparations - The invention relates to compounds of the general formula (I), where R | 2013-05-23 |